PARABDRUGS

Parabolic Drugs Limited has informed the Exchange vide letter dated August 16, 2012 regarding a press release dated August 14, 2012, titled "Parabolic Drugs' Q1 FY 13 sales up 64% to Rs 305.20 Crores, Launches new products in the non-antibiotic segment, The Board of Directors recommends a dividend of Rs.0.25 per share".

Parabolic Drugs Limited has informed the Exchange, vide its letter dated May 12, 2012, regarding a press release, titled "Parabolic Drugs' FY12 Sales up 50.3% to Rs 1014.9 crore Net Profit at 51.4 Cr".

Parabolic Drugs Limited has informed the Exchange, vide its letter dated February 11, 2012, regarding a press release dated February 11, 2012, titled "Parabolic Drugs' 9M FY12 sales up 54.39% to Rs 719.51 crore; Net profit up 13.66% to Rs.42.39 Crore".

Parabolic Drugs Limited has informed the Exchange, vide its letter dated November 12, 2011, regarding a press release, titled "Parabolic Drugs' H1FY12 sales up 39.49% to Rs 420.66 crore; Net Profit up 19.12% to Rs.29.57 Crore".

Parabolic Drugs Limited has informed the Exchange vide its letter dated October 31, 2011 regarding a press release, titled "Parabolic Drugs gets Japanese nod for Cephalosporin Drugs".

Parabolic Drugs Limited has informed the Exchange vide its letter dated September 02, 2011 regarding a press release, titled "Parabolic Drugs adds 15% capacity to its Cephalosporin facility commissions its 8th Multi-purpose plant at Derabassi facility".

Parabolic Drugs Limited has informed the Exchange vide its letter dated August 13, 2011 regarding a press release with respect to performance of the Company for the quarter ended June 30, 2011.

Parabolic Drugs Limited has informed the Exchange vide its letter dated April 18, 2011 regarding a press release with respect to Certificate of Suitability (COS) granted to the Company in respect of its one of key molecule namely "Cefixime".

Parabolic Drugs Limited has informed the Exchange, vide its letter dated February 02, 2011, regarding a press release, titled "Parabolic Drugs' 9MFY11 net profit up 65.6% to Rs.37.30 crore; Sales up 24.4% to Rs.466.04 crore".

Parabolic Drugs Limited has informed the Exchange regarding a press release dated July 12, 2010, titled "Parabolic Drugs Gets EU GMP Approval for its facility".

Parabolic Drugs Limited has informed the Exchange vide its letter dated June 30, 2010 regarding a press release with respect to Audited Financial Results of the Company for the quarter / year ended March 31, 2010.